BlackRock’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-15,165
| Closed | -$295K | – | 5583 |
|
|
2024
Q4 | $295K | Sell |
15,165
-569
| -4% | -$10.6K | ﹤0.01% | 4543 |
|
|
2024
Q3 | $247K | Sell |
15,734
-4,703
| -23% | -$41.8K | ﹤0.01% | 4482 |
|
|
2024
Q2 | $173K | Sell |
20,437
-4,187
| -17% | -$49K | ﹤0.01% | 4578 |
|
|
2024
Q1 | $380K | Sell |
24,624
-3,163
| -11% | -$48.3K | ﹤0.01% | 4454 |
|
|
2023
Q4 | $384K | Sell |
27,787
-1,083
| -4% | -$12.8K | ﹤0.01% | 4488 |
|
|
2023
Q3 | $330K | Sell |
28,870
-240
| -0.8% | -$4.46K | ﹤0.01% | 4538 |
|
|
2023
Q2 | $725K | Sell |
29,110
-86,768
| -75% | -$2.54M | ﹤0.01% | 4378 |
|
|
2023
Q1 | $4.21M | Sell |
115,878
-2,613
| -2% | -$160K | ﹤0.01% | 3703 |
|
|
2022
Q4 | $7.14M | Sell |
118,491
-6,413
| -5% | -$430K | ﹤0.01% | 3551 |
|
|
2022
Q3 | $9.37M | Buy |
124,904
+10,369
| +9% | +$1.08M | ﹤0.01% | 3464 |
|
|
2022
Q2 | $13.1M | Buy |
114,535
+20,179
| +21% | +$2.37M | ﹤0.01% | 3350 |
|
|
2022
Q1 | $17.9M | Buy |
94,356
+56,694
| +151% | +$13.1M | ﹤0.01% | 3241 |
|
|
2021
Q4 | $13.1M | Buy |
37,662
+16,360
| +77% | +$6.34M | ﹤0.01% | 3512 |
|
|
2021
Q3 | $7.15M | Buy |
21,302
+19,107
| +870% | +$9.8M | ﹤0.01% | 3821 |
|
|
2021
Q2 | $1.81M | Buy |
+2,195
| New | +$1.7M | ﹤0.01% | 4319 |
|
BlackRock's OMIC Position: Q1 2025 in Review
BlackRock sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q1 2025, closing a stake of 15,165 shares — an estimated $295K sold.
BlackRock first reported a position in OMIC in Q2 2021 and held it in 15 quarters. The position peaked at $17.9M in Q1 2022. 0 funds tracked by Wall St. Rank hold OMIC as of Q1 2025.
- BlackRock reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- BlackRock sold 15,165 Singular Genomics Systems, Inc. Common Stock shares in Q1 2025, an estimated $295K.
- BlackRock first reported a position in Singular Genomics Systems, Inc. Common Stock in Q2 2021 and held it in 15 quarters.
- BlackRock's Singular Genomics Systems, Inc. Common Stock position peaked at $17.9M in Q1 2022.
- 0 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q1 2025.
Based on BlackRock's 13F filing for Q1 2025, filed 2 May 2025.